Loading provider…
- Featuresarrow_drop_down
- Solutionsarrow_drop_down
Loading provider…
Your Medical Sales Assistants that help you easily find, convert and close your ideal providersHematology & Oncology Physician in Chicago, IL
NPI: 1356522460Primary Practice Location
THE UNIVERSITY OF CHICAGO MEDICAL CENTER
5700 S Maryland Ave, Chicago, IL
Primary Employer
The University of Chicago Medical Center
uchicagomedicine.org
HQ Phone
Get Michael's Phone Numberphone_androidMobile
Get Michael's MobileLooking to connect with more Physicians?
Dmand AI gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Get Started for Freearrow_outwardIL State Medical License
| # | Procedure Code (CPT®/HCPCS II) | Procedure Patients | Procedure Volume |
|---|---|---|---|
| 1 | 99214Established patient office or other outpatient visit, 30-39 minutes | 44 | 98 |
| 2 | 99233Subsequent hospital inpatient care, typically 35 minutes per day | 40 | 259 |
| 3 | 99215Established patient office or other outpatient, visit typically 40 minutes | 32 | 89 |
| 4 | 99223Initial hospital inpatient care, typically 70 minutes per day | 23 | 24 |
| 5 | 99213Established patient office or other outpatient visit, typically 15 minutes | 16 | 38 |
Authors: Ahmad Rayes
Journal: Cancer Cell
Authors: Baron, Beverly W, Thirman, Michael J, Giurcanu, Mihai C, Baron, Joseph M
Journal: Acta Haematol
Publication Date: 2018-02-14
High dose cytarabine and mitoxantrone: an effective induction regimen for high-risk acute myeloid leukemia (AML).
Authors: Richard Larson, Christopher Daugherty, Lucy Godley, Olatoyosi Odenike, Margaret Green
Publication Date: 2011-09-15
Lead Sponsor: Sumitomo Pharma America, Inc.
Intervention / Treatment: COMBINATION_PRODUCT: Alvocidib Plus Decitabine (during dose escalation only) or Azacitidine
Lead Sponsor: National Cancer Institute (NCI)
Intervention / Treatment: PROCEDURE: Bone Marrow Biopsy, DRUG: Venetoclax, PROCEDURE: Biospecimen Collection, OTHER: Quality-of-Life Assessment, DRUG: Ibrutinib, PROCEDURE: Computed Tomography, BIOLOGICAL: Obinutuzumab
Lead Sponsor: National Cancer Institute (NCI)
Intervention / Treatment: DRUG: Venetoclax, DRUG: Ibrutinib, BIOLOGICAL: Obinutuzumab, OTHER: Observation Activity
